Gerstner Elizabeth R, Batchelor Tracy T
Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
Arch Neurol. 2010 Mar;67(3):291-7. doi: 10.1001/archneurol.2010.3.
Primary central nervous system (CNS) lymphoma (PCNSL), an uncommon variant of extranodal non-Hodgkin lymphoma (NHL), can affect any part of the neuraxis including the eyes, brain, leptomeninges, or spinal cord. It accounts for approximately 3% of all the primary CNS tumors diagnosed each year in the United States. Congenital or acquired immunodeficiency is the only established risk factor for PCNSL, and individuals with human immunodeficiency virus (HIV) infection are at greater risk for developing this tumor. Infection with HIV likely accounted for the increased incidence in PCNSL observed from 1970 to 2000, but over the last decade the number of cases of PCNSL has stabilized or decreased to about 0.47 cases per 100 000 persons. Owing to the rarity of PCNSL, the disease has been challenging to study and an effective standard of care has been difficult to establish. Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host.
原发性中枢神经系统(CNS)淋巴瘤(PCNSL)是结外非霍奇金淋巴瘤(NHL)的一种罕见变体,可累及神经轴的任何部位,包括眼睛、大脑、软脑膜或脊髓。它约占美国每年诊断出的所有原发性CNS肿瘤的3%。先天性或获得性免疫缺陷是PCNSL唯一已确定的危险因素,感染人类免疫缺陷病毒(HIV)的个体患这种肿瘤的风险更高。HIV感染可能是1970年至2000年期间观察到的PCNSL发病率增加的原因,但在过去十年中,PCNSL的病例数已趋于稳定或下降至每10万人约0.47例。由于PCNSL罕见,对该疾病的研究具有挑战性,难以确立有效的标准治疗方案。不幸的是,尽管一些PCNSL患者可能实现持久缓解,但大多数情况下肿瘤会复发。在本综述中,我们将重点关注免疫功能正常宿主中的PCNSL。